Skip to main content
. 2010 Jan 29;37(2):159–171. doi: 10.1016/j.molcel.2009.12.023

Figure 4.

Figure 4

Analysis of WT1 in HtrA2 Null MEFs

(A) Whole-cell lysates were prepared from HtrA2+/+ or HtrA2−/− mouse embryonic fibroblasts (MEFs) and compared with mouse M15 cells by immunoblotting.

(B) HtrA2+/+ or HtrA2−/− MEFs were transfected with control siRNA or with WT1-specific siRNA, and 30 hr later, whole-cell lysates were prepared and immunoblotted with the antibodies indicated.

(C) M15 cells or HtrA2−/− MEFs were stimulated for 8 hr with 0.5 μM Staurosporine or 5 ng/ml Anisomycin, and whole-cell lysates were prepared and immunoblotted with the antibodies indicated.

(D) HtrA2−/− MEFS were transfected with control vector (pCDNA3), vector driving expression of wild-type HtrA2, or the HtrA2 mutant derivative S306A. Whole-cell lysates were immunoblotted with the antibodies indicated. The full-length and processed forms of HtrA2 are indicated.

(E) HtrA2−/− MEFS were cotransfected with a vector driving expression of GFP along with either control vector (pCDNA3) and vector driving expression of wild-type HtrA2 or the HtrA2 mutant derivative S306A. The cells were analyzed by immunofluorescence with anti-WT1 antibodies (red) and overlayed with the GFP signal.